Thomas M. Rinderknecht, PhD, has served as a member of the Board of Directors of ADC Therapeutics since 2016.
Dr. Rinderknecht is a senior partner at the law firm Badertscher Rechtsanwälte AG, in Zurich and Zug. He has served on the Boards of Directors of several biotech, pharma, and medtech companies, including Skye Pharma Ltd., London, UK; Speedel AG, Basel, CH; Glycart Biotechnology AG, Schlieren, CH; and Ganymed Pharmaceuticals AG, Mainz, Germany. He currently serves as Vice Chairman of the listed company Basilea Pharmaceutica AG, Basel; as Chairman of Canyon Pharmaceuticals AG, Zug; and Vice Chairman of APR Applied Pharma Research SA, Balerna, CH. He also serves on the board of Lindt & Spruengli and several other firms in the media, hotel, and industry sector.
Dr. Rinderknecht holds a PhD in law from the University of Zurich and is admitted to the Bar in Zurich and Zug.